Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$391.78M

FY 2025 · Annual

Investing Cash Flow

$310.37M

FY 2025 · Annual

-37.8% YoY

Financing Cash Flow

$3.79M

FY 2025 · Annual

-13.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Depreciation & Amortization5.81M6.78M19.45M14.56M21.15M
Deferred Income Tax15.19M(15.19M)(1.06M)(2.95M)0
Stock-Based Compensation83.78M102.08M078.46M49.07M
Change in Working Capital(628.39M)665.37M(304.59M)(84.01M)(22.45M)
Accounts Receivables(773.08M)770.04M(565K)(6.51M)0
Inventory52.82M0000
Accounts Payables(171K)797K732K(988K)5M
Other Working Capital92.04M(105.47M)(304.76M)(76.51M)(27.44M)
Other Non-Cash Items(52.56M)388.37M122.48M69.55M(1.57M)
Operating Cash Flow(47.59M)1.66B(778.79M)(446.35M)(391.78M)
Capital Expenditures(21.82M)(68.01M)(21.57M)(7.3M)(4.83M)
Acquisitions (Net)140.81M0100K3.37M253K
Purchases of Investments(420.24M)(1.48B)(2.02B)(1.24B)(886.33M)
Sales of Investments301.24M351.51M2.2B1.74B1.2B
Other Investing Activities(140.81M)0000
Investing Cash Flow(140.81M)(1.19B)164.73M499.37M310.37M
Debt Repayment(259K)(260K)(287K)(165K)(361K)
Common Stock Issued85.21M28.46M7.77M4.55M4.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.38M6.56M(100K)00
Financing Cash Flow100.33M34.76M7.38M4.39M3.79M
Effect of Forex Changes00208K00
Net Change in Cash(88.07M)504.55M(606.47M)57.4M(77.63M)
Free Cash Flow(69.41M)1.6B(800.36M)(453.65M)(396.61M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$438.0M
+ D&A$21.2M
+ Stock-Based Comp$49.1M
+ Deferred Tax$0
- Working Capital-$22.4M
- Other Non-Cash-$1.6M
= Operating Cash Flow-$391.8M
- Capex-$4.8M
= Free Cash Flow-$396.6M

Analysis

FY2025 free cash flow is -$396.6M. FCF conversion is 90.6% of net income. Operating cash flow was -$391.8M, with capex of -$4.8M. The largest bridge item is Stock-Based Comp at $49.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
424B5424B5 filingNov 12, 2026
S-3ASRS-3ASR filingNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 9, 2026
SC 13D/ASC 13D/A filingNov 6, 2026

Does VIR generate free cash flow?

Vir Biotechnology, Inc. (VIR) generated -$396.61M of free cash flow in fiscal 2025.

How much operating cash flow does VIR produce?

Operating cash flow was -$391.78M, before capital expenditures of $4.83M.